Promote the proliferation of spleen germinal centers and make lymphocytes proliferate in large numbers.
Enhance lymphocyte activity and exert immune surveillance and anti-tumor functions.
Promote lymphocytes to secrete endogenous interferon, IL-2, TNF, and kill tumor cells.
Change the activity of lectin receptors on tumor cell membranes, making tumor cells easier to capture and kill.
NO TOXICITY
HIGH EFFECTIVENESS
NO SIMPLE USE
PROPER COST
Prevent and reduce recurrence, used for postoperative patients with extremely high recurrence and ineffective radiotherapy and chemotherapy
Convenient and effective, quickly relieve symptoms
Improve the comprehensive treatment effect of tumors
Control cancer and coexist with cancer
Bring new opportunities to cancer patients with no hope of survival
Patients with early tumors who need to prevent recurrence after conventional treatment;
Patients with advanced tumors who combine conventional treatment (surgery, chemotherapy and radiotherapy) to improve efficacy and prolong survival;
Patients with advanced cancer who progress after conventional treatment and improve their quality of life.
Male, 67 years old, liver cancer with portal vein tumor thrombus;
Had undergone interventional embolization chemotherapy twice;
Oral targeted drugs were discontinued due to severe side effects;
Anti-tumor combined immunotherapy was started in November 2023, 1 ml each time;
CT reexamination in May 2024 showed tumor shrinkage;
PET/CT reexamination in July 2024 showed no active tumor.
Male, 56 years old, multiple metastases of lung cancer (mediastinum, lung, liver, spine and pelvis, etc.);
Have undergone targeted, immunotherapy and local ablation therapy, NK cell therapy, hydrogen and oxygen inhalation, etc.;
Anti-tumor compound immunotherapy from April 2024 to date, 0.5-1.0ml each time;
Current efficacy CR.
Origin of bacterial vaccines and tumor immunotherapy
1893: The invention of Coley toxin pioneered bacterial vaccines and tumor immunotherapy.
1959: BCG (Single bacterial vaccine) is the first bacterial vaccine product successfully used in cancer treatment.
What is anti-tumor compound immunotherapy?
TTV is called A new type Tumor Treatment Vaccine. It is a compound preparation composed of 8 bacterial components and a virus, biological excipients and chemical adjuvant components, and is prepared through coupling, emulsification and sterilization processes.
Continue and develop the great practice of Coley, the "father of cancer immunotherapy" more than a hundred years ago: patients have a history of bacterial infection before and after the self-healing of cancer. This may be the key to the "self-healing" of cancer.
Follow and practice the innovative anti-cancer concept of Academician Wang Zhenyi, the "father of cancer-induced differentiation": cancer cell diversity, immune cells must also be diverse, cancer cell instability, immune cells must adapt to changes, cancer cell persistence: apoptosis, dormancy, resurrection, immunotherapy should be a long-term principle.
"Cancer volunteer Professor Xu Kecheng" tried it himself, and wrote "real world evidence" with the miracle of life: strive to study new treatment options, coexist with cancer, and finally succeed in anti-cancer.
Mechanism of action of anti-tumor combined immunotherapy (TTV)
Features of TTV
Five functions of TTV
Indications of TTV:
TTV developer
Academician Wang Zhenyi
Wang Zhenyi, a centenarian, was awarded the "Medal of the Republic". On September 13, 2024, President Xi Jinping signed a presidential decree to award 15 people with national medals and honorary titles according to the decision of the Standing Committee of the National People's Congress on awarding national medals and honorary titles on the occasion of the 75th anniversary of the founding of the People's Republic of China, which was voted and passed at the 11th meeting of the Standing Committee of the 14th National People's Congress on the morning of the 13th.
Among them, Wang Zhenyi, former president of Shanghai Second Medical University (now Shanghai Jiaotong University School of Medicine), former director of Shanghai Institute of Hematology, lifelong professor of Ruijin Hospital, academician of the Chinese Academy of Engineering, and winner of the National Highest Science and Technology Award, was awarded the "Medal of the Republic".
Professor Wang Zhenyi Wang Zhenyi is mainly engaged in hematology research. He is one of the pioneers of thrombosis and hemostasis in China and is known as the "father of cancer-induced differentiation". The International Astronomical Center permanently named asteroid 43259 as "Wang Zhenyi Star".
Professor Xu Kecheng
Gastroenterologist and tumor treatment expert; Honorary Dean of the Institute of Biomedical Translation of Jinan University; Legal person and Honorary Chairman of the Asian Society of Cryosurgery; Winner of the Bethune Medal.
He made a major breakthrough in the treatment of pancreatic cancer and won the gold medal at the 35th Annual Meeting of the Japanese Society of Cryogenics. In 2014, he was awarded the title of China's Model of the Times by the Central Propaganda Department at the Model of the Times Press Conference Hall of CCTV and was hailed as a cancer killer. He has edited more than 10 monographs and published more than 100 papers.
Patent of TTV
Related research on TTV
Case of Indonesian patients using combined immunization method
Liver cancer
Lung adenocarcinoma
